Preview Mode Links will not work in preview mode

COVID-19 Evidence presented by InpharmD™

Feb 26, 2021

Early data suggests the incidence of true anaphylaxis to the Pfizer-BioNTech COVID-19 vaccine is rare (11.1 cases per million vaccine doses). Anaphylaxis is more common in women and persons with a history of allergies, and symptoms typically appear within 30 minutes of injection.


Feb 19, 2021

A retrospective, observational, cohort study done to assess whether a diagnosis of a schizophrenia spectrum disorder, mood disorder, or anxiety disorder is associated with mortality in patients with COVID-19.


Feb 8, 2021

A randomized, multicenter, double-blind, placebo-controlled, phase 1/2a clinical trial to evaluate the safety, reactogenicity, and immunogenicity of Ad26.COV2.S - a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein


Feb 1, 2021

An observational cohort study performed to describe characteristics and outcomes of hematopoietic stem-cell transplantation (HSCT) recipients after developing COVID-19